FDA Clearance Tracker · P160037-S003
BD Onclarity HPV Assay
Last checked: Nov 20, 2026Latest source record: Nov 22, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Nov 22, 2019
Approved
Time to decision
93 days
Received Aug 21, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160037-S003
- Device name
- BD Onclarity HPV Assay
- Applicant
- Becton, Dickinson and Company
- Applicant location
- Sparks, MD
- Received
- Aug 21, 2019
- Decided
- Nov 22, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P160037
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for a post approval study labeling update.
Source documents
Other decisions for Becton, Dickinson and Company
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252344 · Decided Oct 16, 2026 · 445 days after receipt
Device type: Tubes, Vials, Systems, Serum Separators, Blood Collection (JKA) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.